185 related articles for article (PubMed ID: 29127277)
1. Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Hammam K; Saez-Ayala M; Rebuffet E; Gros L; Lopez S; Hajem B; Humbert M; Baudelet E; Audebert S; Betzi S; Lugari A; Combes S; Letard S; Casteran N; Mansfield C; Moussy A; De Sepulveda P; Morelli X; Dubreuil P
Nat Commun; 2017 Nov; 8(1):1420. PubMed ID: 29127277
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
3. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Thamm DH; Rose B; Kow K; Humbert M; Mansfield CD; Moussy A; Hermine O; Dubreuil P
Vet J; 2012 Jan; 191(1):131-4. PubMed ID: 21333567
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
6. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
[TBL] [Abstract][Full Text] [Related]
7. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
[TBL] [Abstract][Full Text] [Related]
9. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
10. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
Kocabas NA; Aksoy P; Pelleymounter LL; Moon I; Ryu JS; Gilbert JA; Salavaggione OE; Eckloff BW; Wieben ED; Yee V; Weinshilboum RM; Ames MM
Drug Metab Dispos; 2008 Sep; 36(9):1951-9. PubMed ID: 18556440
[TBL] [Abstract][Full Text] [Related]
12. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
13. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
14. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Humbert M; Castéran N; Letard S; Hanssens K; Iovanna J; Finetti P; Bertucci F; Bader T; Mansfield CD; Moussy A; Hermine O; Dubreuil P
PLoS One; 2010 Mar; 5(3):e9430. PubMed ID: 20209107
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
Nakano T; Saiki Y; Kudo C; Hirayama A; Mizuguchi Y; Fujiwara S; Soga T; Sunamura M; Matsumura N; Motoi F; Unno M; Horii A
Biochem Biophys Res Commun; 2015 Sep; 464(4):1084-1089. PubMed ID: 26196746
[TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
17. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
18. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
Leisewitz AV; Zimmerman EI; Jones SZ; Yang J; Graves LM
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):779-86. PubMed ID: 18600540
[TBL] [Abstract][Full Text] [Related]
19. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Ueda K; Masuda A; Fukuda M; Tanaka S; Hosokawa M; Iwakawa S
Drug Metab Pharmacokinet; 2017 Dec; 32(6):301-310. PubMed ID: 29174536
[TBL] [Abstract][Full Text] [Related]
20. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
